Background:The purpose of this report is to summarize the evidence supporting supplementation of n-3 polyunsaturated fatty acids(n-3 PUFAs)in adult cancer patients,and to offer a better understanding of the appropriat...Background:The purpose of this report is to summarize the evidence supporting supplementation of n-3 polyunsaturated fatty acids(n-3 PUFAs)in adult cancer patients,and to offer a better understanding of the appropriate use of n-3 PUFAs in the clinical setting.Methods:Numerous databases were searched for guidelines,clinical decision-making documents,systematic reviews,expert consensus statements,and best evidence summaries about the use of n-3 PUFAs in cancer patients from the inception of the database to December 31,2023.Evidence grading and recommendation rating were conducted.The data extracted included the timing of supplementation,symptom management,disease prevention,cost-effectiveness,route of administration,application scenarios,dosage,and safety.Results:The collected data show that n-3 PUFAs are safe for patients receiving chemotherapy who are at risk of malnutrition and cachexia.Moreover,n-3 PUFA supplementation can alleviate the adverse symptoms associated with chemotherapy,extend survival,and improve the quality of life of patients with cancer.Conclusions:The administration of supplementary n-3 PUFAs should be considered based on the patient’s disease stage,treatment plan,nutritional status,and tolerance,as well as the dosage,route and application scenarios.Promoting the clinical use of n-3 PUFAs may improve the outcomes for patients with cancer.展开更多
文摘Background:The purpose of this report is to summarize the evidence supporting supplementation of n-3 polyunsaturated fatty acids(n-3 PUFAs)in adult cancer patients,and to offer a better understanding of the appropriate use of n-3 PUFAs in the clinical setting.Methods:Numerous databases were searched for guidelines,clinical decision-making documents,systematic reviews,expert consensus statements,and best evidence summaries about the use of n-3 PUFAs in cancer patients from the inception of the database to December 31,2023.Evidence grading and recommendation rating were conducted.The data extracted included the timing of supplementation,symptom management,disease prevention,cost-effectiveness,route of administration,application scenarios,dosage,and safety.Results:The collected data show that n-3 PUFAs are safe for patients receiving chemotherapy who are at risk of malnutrition and cachexia.Moreover,n-3 PUFA supplementation can alleviate the adverse symptoms associated with chemotherapy,extend survival,and improve the quality of life of patients with cancer.Conclusions:The administration of supplementary n-3 PUFAs should be considered based on the patient’s disease stage,treatment plan,nutritional status,and tolerance,as well as the dosage,route and application scenarios.Promoting the clinical use of n-3 PUFAs may improve the outcomes for patients with cancer.
